X
Xia Xu
Researcher at Pfizer
Publications - 23
Citations - 2937
Xia Xu is an academic researcher from Pfizer. The author has contributed to research in topics: Raltegravir & Emtricitabine. The author has an hindex of 14, co-authored 23 publications receiving 1638 citations. Previous affiliations of Xia Xu include Merck & Co..
Papers
More filters
Journal ArticleDOI
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox,Edwin DeJesus,Adriano Lazzarin,Richard B. Pollard,José Valdez Madruga,Daniel S Berger,Jing Zhao,Xia Xu,Angela Williams-Diaz,Anthony Rodgers,Richard J. O. Barnard,Michael D. Miller,Mark J. DiNubile,Bach-Yen Nguyen,Randi Y. Leavitt,Peter Sklar +15 more
TL;DR: Raltegravir is a well tolerated alternative to efavirenz as part of a combination regimen against HIV-1 in treatment-naive patients and has rapid and potent antiretroviral activity, which was non-inferior to that of efvirenz at week 48.
Journal ArticleDOI
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
Robert W. Frenck,Nicola P. Klein,Nicholas Kitchin,Alejandra Gurtman,Judith Absalon,Stephen Lockhart,John L. Perez,Emmanuel B. Walter,Shelly Senders,Ruth Bailey,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Warren Kalina,David K. C. Cooper,Timothy Jennings,Donald M Brandon,Stephen J. Thomas,Özlem Türeci,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +25 more
TL;DR: The vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of.
Journal ArticleDOI
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Emmanuel B. Walter,Kawsar R. Talaat,Charu Sabharwal,Alejandra Gurtman,Stephen Lockhart,Grant Paulsen,Elizabeth D. Barnett,Flor M. Munoz,Yvonne Maldonado,Barbara A. Pahud,Joseph B. Domachowske,Eric A. F. Simões,Uzma N. Sarwar,Nicholas Kitchin,Luke Cunliffe,Pablo Rojo,Ernest Kuchar,Mika Rämet,Iona Munjal,John L. Perez,Robert W. Frenck,Eleni Lagkadinou,Kena A. Swanson,Hua Ma,Xia Xu,Kenneth Koury,Susan Mather,Todd Belanger,David K. C. Cooper,Özlem Türeci,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +33 more
TL;DR: A phase 1, dose-finding study and an ongoing phase 2-3 randomized trial are being conducted to investigate the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in children 6 months to 11 years of age.
Journal ArticleDOI
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Joseph J. Eron,Benjamin Young,David A. Cooper,Mike Youle,Edwin DeJesus,Jaime Andrade-Villanueva,Cassy Workman,Roberto Zajdenverg,Gerd Fätkenheuer,Daniel S Berger,Princy Kumar,Anthony Rodgers,Melissa Shaughnessy,Monica L. Walker,Richard J. O. Barnard,Michael D. Miller,Mark J. DiNubile,Bach-Yen Nguyen,Randi Y. Leavitt,Xia Xu,Peter Sklar +20 more
TL;DR: Although switching to raltegravir was associated with greater reductions in serum lipid concentrations than was continuation of lopinavir-ritonavir, efficacy results did not establish non-inferiority of ral Teva, and the studies were terminated at week 24 because of lower than expected virological efficacy.
Journal ArticleDOI
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
Ann R. Falsey,Robert W. Frenck,Edward E. Walsh,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,Ruth Bailey,Kena A. Swanson,Xia Xu,Kenneth Koury,Warren Kalina,David A. Cooper,Jing Zou,Xuping Xie,Hongjie Xia,Özlem Türeci,Eleni Lagkadinou,Tompkins Kristin Rachael,Pei Yong Shi,Kathrin U. Jansen,Ugur Sahin,Philip R. Dormitzer,William C. Gruber +23 more
TL;DR: In this paper, a third dose of the BNT162b2 vaccine was administered to 23 volunteers 8 to 9 months after the second dose, and the immune response was assessed.